Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06950294 · ClinicalTrials.gov registry record · Early Phase 1
iNO300 Therapy in Critically Ill Patients With Pneumonia
A Early Phase 1 study of Critical Illness and Pneumonia, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT06950294 is a Early Phase 1 study of Critical Illness and Pneumonia that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 34 participants, below the 3,138-participant average among 91 other Critical Illness trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06950294, a Early Phase 1 study of Critical Illness and Pneumonia, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn the formation and recovery rate of methemoglobin (MetHb) in severely sick patients with pneumonia who receive high doses of inhaled nitric oxide (iNO) therapy at 250 parts per million (ppm), not exceeding 300 ppm. Meanwhile, the benefits of the therapy to treat severely sick patients with pneumonia will be explored. Patients who are 18 years or older, newly diagnosed with pneumonia, and severely sick with requirement of a breathing machine could be included. The main questions it aims to answer are: How does methemoglobin change through the iNO treatment? Does iNO therapy increase the number of patients recovering from pneumonia? Researchers will compare iNO treatment to placebo, which means using the same device as the treatment group without delivering the study drug. Participants will: * Receive iNO treatment starting at 250 ppm, not exceeding 300 ppm, 40 min, every 6 hours, from day 1 to day 5 * Be followed up for 60 days
Conditions Studied
Interventions
- DRUG High dose inhaled nitric oxide
- OTHER Sham treatment
- OTHER standard therapy
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2026-02-23 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06950294
The ClinicalTrials.gov registry entry for NCT06950294 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,138-participant average among 91 other Critical Illness trials with a reported enrollment target (99% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Critical Illness appearing as the primary indexed condition, and to 3 interventions - of which High dose inhaled nitric oxide is the first listed.
NCT06950294 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06950294 about?
NCT06950294 is a clinical study titled "iNO300 Therapy in Critically Ill Patients With Pneumonia". The goal of this clinical trial is to learn the formation and recovery rate of methemoglobin (MetHb) in severely sick patients with pneumonia who receive high doses of inhaled nitric oxide (iNO) therapy at 250 parts per million (ppm), not exceeding 300 ppm. Meanwhile, the benefits of the therapy to ...
What is the current status of trial NCT06950294?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 34 participants. The study started on 2026-02-23. Estimated completion is 2026-12.
What conditions does trial NCT06950294 study?
This clinical trial studies the following conditions: Critical Illness, Pneumonia.
What interventions are being tested in trial NCT06950294?
The interventions under investigation include: High dose inhaled nitric oxide (DRUG), Sham treatment (OTHER), standard therapy (OTHER).
Who is sponsoring clinical trial NCT06950294?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06950294 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Critical Illness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
RECRUITING · NA
-
Assessment of Stroke Volume in Shock Using Echocardiography Versus Bioreactive Impedance
RECRUITING
-
Improving Needs Among Older Adults
RECRUITING · NA
-
The Family Perspectives Project Pilot Trial
RECRUITING · NA
-
Safety and Feasibility of a Self-Balancing Exoskeleton for Rehabilitation in the Thoracic Surgical Intensive Care Unit: a Pilot Trial
RECRUITING · Phase 1
-
12-hour Time Limited Feeding in Critical Care
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.